Inclisiran Formulations for Safety and Tolerability

This trial tests a new formulation of inclisiran, a drug aimed at managing cholesterol levels, to determine its safety and tolerability. Researchers compare the current version of inclisiran with a new version that includes polysorbate 80. The trial targets healthy individuals who are not using cholesterol-lowering medications and have higher levels of LDL cholesterol, often called "bad" cholesterol. Participants must not have used statins before and should have no history of familial high cholesterol. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new formulation.

Research has shown that inclisiran, the main ingredient in both parts of the trial, is generally well-tolerated. It is already approved for adults with high cholesterol, providing some confidence in its safety. Earlier studies tested inclisiran in over 1,800 patients, with more than 1,600 using it for up to 18 months, and these studies did not identify major safety concerns.

Specific safety information for the new version that includes polysorbate 80 is not yet available. However, the trial will compare it to the version already on the market, suggesting both are expected to have similar safety profiles.

Most treatments for high cholesterol, like statins, work by reducing the production of cholesterol in the liver. Inclisiran is unique because it targets a different pathway, using RNA interference to reduce the production of a protein called PCSK9, which increases the liver's ability to remove LDL cholesterol, or "bad cholesterol," from the blood. Researchers are excited about the new formulation containing Polysorbate 80 because it may enhance the delivery and effectiveness of Inclisiran, potentially leading to better outcomes with fewer doses. This could mean a more convenient treatment option for patients, with lasting effects from just a single dose.

Research has shown that inclisiran effectively lowers LDL cholesterol, often referred to as "bad" cholesterol. Studies have found it can reduce LDL levels by about 50% with just two doses over several months, making it a strong option for individuals who struggle to lower cholesterol with other treatments. The drug has been well tolerated, with common side effects being mild, such as reactions at the injection site. In this trial, participants will receive either the currently marketed formulation of inclisiran or a new version containing an ingredient called polysorbate 80. Researchers are testing the new formulation to determine if it is equally safe and effective, or even better.⁶⁷⁸⁹¹⁰